Medications

FDA panel: Expand use of fish oil drug Vascepa

Approved use of the prescription-strength fish oil drug Vascepa should be widened to include more patients at risk for heart attack and stroke, a U.S. Food and Drug Administration advisory panel recommended Thursday.

Medications

FDA: Pulmonary embolism risk up with tofacitinib 10 mg for RA

(HealthDay)—A safety clinical trial has revealed that tofacitinib (Xeljanz, Xeljanz XR) 10 mg twice daily is associated with an increased risk for pulmonary embolism (PE) and death among patients with rheumatoid arthritis ...

Diseases, Conditions, Syndromes

Review finds antibiotic development increased, but insufficient

While the pipeline of new antibiotics has improved over the past six years, momentum in the development of new infection-fighting agents remains inadequate and could take a significant downturn without new incentives, a report ...

Medications

Many drugs made available via FDA expanded access programs

(HealthDay)—Over the past two decades, close to 100 U.S. Food and Drug Administration (FDA)-approved drugs and biologics were made available before FDA approval through expanded access programs, according to a study published ...

page 8 from 18